So ask your doctor what factors cause major bleeding or gastrointestinal bleeding from use of aspirin.
The efficacy and safety of aspirin as the primary prevention of cardiovascular disease: An updated meta-analysis
Therapeutics and Clinical Risk Management — Xie W, et al. | September 26, 2019
Researchers performed an updated
meta-analysis of 14 studies to assess the efficacy and safety of aspirin
for the primary prevention of cardiovascular disease. Eligible studies
included randomized, controlled trials comparing aspirin with placebo or
no treatment that were published up to November 1, 2018. The primary
efficacy endpoint was all-cause death, with secondary endpoints
including cardiovascular death, myocardial infarction, and stroke. Major
bleeding, gastrointestinal bleeding, and hemorrhagic stroke comprised
safety endpoints. Compared with placebo or no treatment, aspirin was
linked to a lower risk of myocardial infarction. Compared with control
groups, however, aspirin was no linked to a lower risk of all-cause
mortality or cardiovascular mortality. With respect to safety, aspirin
was associated with a higher risk of major bleeding, gastrointestinal
bleeding, and hemorrhagic stroke. In addition, patients’ clinical
characteristics did not greatly influence the treatment affect.
Read the full article on Therapeutics and Clinical Risk Management
No comments:
Post a Comment